Literature DB >> 31059647

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.

Carl C Ward1,2, Jordan I Kleinman2,3, Scott M Brittain2,4, Patrick S Lee2,5, Clive Yik Sham Chung2,3, Kenneth Kim1,2, Yana Petri2,3, Jason R Thomas2,4, John A Tallarico2,4, Jeffrey M McKenna2,4, Markus Schirle2,4, Daniel K Nomura1,2,3,6.   

Abstract

Targeted protein degradation has arisen as a powerful strategy for drug discovery allowing the targeting of undruggable proteins for proteasomal degradation. This approach most often employs heterobifunctional degraders consisting of a protein-targeting ligand linked to an E3 ligase recruiter to ubiquitinate and mark proteins of interest for proteasomal degradation. One challenge with this approach, however, is that only a few E3 ligase recruiters currently exist for targeted protein degradation applications, despite the hundreds of known E3 ligases in the human genome. Here, we utilized activity-based protein profiling (ABPP)-based covalent ligand screening approaches to identify cysteine-reactive small-molecules that react with the E3 ubiquitin ligase RNF4 and provide chemical starting points for the design of RNF4-based degraders. The hit covalent ligand from this screen reacted with either of two zinc-coordinating cysteines in the RING domain, C132 and C135, with no effect on RNF4 activity. We further optimized the potency of this hit and incorporated this potential RNF4 recruiter into a bifunctional degrader linked to JQ1, an inhibitor of the BET family of bromodomain proteins. We demonstrate that the resulting compound CCW 28-3 is capable of degrading BRD4 in a proteasome- and RNF4-dependent manner. In this study, we have shown the feasibility of using chemoproteomics-enabled covalent ligand screening platforms to expand the scope of E3 ligase recruiters that can be exploited for targeted protein degradation applications.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31059647      PMCID: PMC7422721          DOI: 10.1021/acschembio.8b01083

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  45 in total

1.  ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity.

Authors:  T Xu; S K Park; J D Venable; J A Wohlschlegel; J K Diedrich; D Cociorva; B Lu; L Liao; J Hewel; X Han; C C L Wong; B Fonslow; C Delahunty; Y Gao; H Shah; J R Yates
Journal:  J Proteomics       Date:  2015-07-11       Impact factor: 4.044

2.  A Photoaffinity Labeling-Based Chemoproteomics Strategy for Unbiased Target Deconvolution of Small Molecule Drug Candidates.

Authors:  Jason R Thomas; Scott M Brittain; Jennifer Lipps; Luis Llamas; Rishi K Jain; Markus Schirle
Journal:  Methods Mol Biol       Date:  2017

3.  Total synthesis of (+/-)-mersicarpine.

Authors:  Jakob Magolan; Cheryl A Carson; Michael A Kerr
Journal:  Org Lett       Date:  2008-03-12       Impact factor: 6.005

4.  Novel 5-arylcarbamoyl-2-methylisoxazolidin-3-yl-3-phosphonates as nucleotide analogues.

Authors:  Kamil Kokosza; Jan Balzarini; Dorota G Piotrowska
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2014       Impact factor: 1.381

5.  Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity.

Authors:  Kimberly E Anderson; Milton To; James A Olzmann; Daniel K Nomura
Journal:  ACS Chem Biol       Date:  2017-09-13       Impact factor: 5.100

6.  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics.

Authors:  Ashley R Schneekloth; Mathieu Pucheault; Hyun Seop Tae; Craig M Crews
Journal:  Bioorg Med Chem Lett       Date:  2008-07-31       Impact factor: 2.823

7.  Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution.

Authors:  Victor J Cee; Laurie P Volak; Yuping Chen; Michael D Bartberger; Chris Tegley; Tara Arvedson; John McCarter; Andrew S Tasker; Christopher Fotsch
Journal:  J Med Chem       Date:  2015-11-18       Impact factor: 7.446

8.  Identification and characterization of small molecule human papillomavirus E6 inhibitors.

Authors:  Kimberly A Malecka; Daniela Fera; David C Schultz; Santosh Hodawadekar; Melvin Reichman; Preston S Donover; Maureen E Murphy; Ronen Marmorstein
Journal:  ACS Chem Biol       Date:  2014-06-02       Impact factor: 5.100

9.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

10.  A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles.

Authors:  Chu Wang; Eranthie Weerapana; Megan M Blewett; Benjamin F Cravatt
Journal:  Nat Methods       Date:  2013-12-01       Impact factor: 28.547

View more
  53 in total

Review 1.  Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective.

Authors:  Xinrui Yang; He Yin; Richard D Kim; Jason B Fleming; Hao Xie
Journal:  Target Oncol       Date:  2020-12-28       Impact factor: 4.493

Review 2.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

3.  A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL.

Authors:  Bingqi Tong; Jessica N Spradlin; Luiz F T Novaes; Erika Zhang; Xirui Hu; Malte Moeller; Scott M Brittain; Lynn M McGregor; Jeffrey M McKenna; John A Tallarico; Markus Schirle; Thomas J Maimone; Daniel K Nomura
Journal:  ACS Chem Biol       Date:  2020-06-25       Impact factor: 5.100

Review 4.  Pharmacological Modulation of Transcriptional Coregulators in Cancer.

Authors:  Timothy R Bishop; Yuxiang Zhang; Michael A Erb
Journal:  Trends Pharmacol Sci       Date:  2019-05-08       Impact factor: 14.819

5.  A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.

Authors:  Karthigayan Shanmugasundaram; Peng Shao; Han Chen; Bismarck Campos; Stanton F McHardy; Tuoping Luo; Hai Rao
Journal:  J Biol Chem       Date:  2019-09-11       Impact factor: 5.157

6.  Parthenolide Covalently Targets and Inhibits Focal Adhesion Kinase in Breast Cancer Cells.

Authors:  Charles A Berdan; Raymond Ho; Haley S Lehtola; Milton To; Xirui Hu; Tucker R Huffman; Yana Petri; Chad R Altobelli; Sasha G Demeulenaere; James A Olzmann; Thomas J Maimone; Daniel K Nomura
Journal:  Cell Chem Biol       Date:  2019-05-09       Impact factor: 8.116

Review 7.  Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.

Authors:  Tinghu Zhang; John M Hatcher; Mingxing Teng; Nathanael S Gray; Milka Kostic
Journal:  Cell Chem Biol       Date:  2019-10-17       Impact factor: 8.116

Review 8.  Targeted protein degradation: elements of PROTAC design.

Authors:  Stacey-Lynn Paiva; Craig M Crews
Journal:  Curr Opin Chem Biol       Date:  2019-04-17       Impact factor: 8.822

Review 9.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

Review 10.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.

Authors:  Tao Wu; Hojong Yoon; Yuan Xiong; Sarah E Dixon-Clarke; Radosław P Nowak; Eric S Fischer
Journal:  Nat Struct Mol Biol       Date:  2020-06-15       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.